CurveBeam AI Posts 18% Purchase Order Growth and Nears $18M Financing Deal
CurveBeam AI reported a solid 18% increase in purchase orders for FY25, alongside record cash receipts and positive operational cash flow in Q4. The company is also advancing a significant vendor financing facility to support growth in key markets.
- 26 purchase orders in FY25, up 18% from prior year
- Record A$5.6 million cash receipts in Q4 FY25
- Positive cash flow of A$0.4 million generated in Q4
- Near-finalisation of A$18 million vendor financing facility
- Progress on enhanced HiRise™ validation and FDA clearance for BMD module
Strong Sales Momentum and Cash Flow Improvement
CurveBeam AI Limited has delivered encouraging operational results in the fourth quarter of FY25, with purchase orders rising to 26 for the full year, an 18% increase compared to 22 orders in the previous corresponding period. The quarter alone saw six new purchase orders, including two for the company’s flagship HiRise™ devices.
Cash receipts from customers hit a record A$5.6 million in Q4, a significant jump from A$1.5 million in the prior quarter. This inflow helped the company generate positive cash flow from operations of A$0.4 million, reversing previous quarters of negative cash flow and signaling improved financial health.
Vendor Financing Facility to Accelerate Growth
CurveBeam is in the final stages of securing an A$18 million (€10 million) vendor financing facility with an international partner. This facility is expected to enable the company to offer leasing options to customers, which could be a game-changer in expanding direct sales across key markets such as North America and Europe. The arrangement also promises to capitalise existing leased devices and support near-term positive cash flows.
Product Development and Regulatory Progress
On the product front, CurveBeam continues to advance validation of its enhanced HiRise™ system with a major robotic surgical system vendor. Engagement has increased positively, and the company remains confident that its submission meets the requirements to complete validation, though timing depends on the vendor’s internal processes.
Additionally, the company is progressing its bone mineral density (BMD) module, having completed 200 of 400 planned patient scans for comparative analysis. The BMD module is on track for FDA 510(k) clearance in the first half of calendar year 2026, which could open new clinical applications and market opportunities.
Financial Position and Outlook
CurveBeam ended Q4 with A$5.0 million in cash and an additional A$5.0 million in receivables from previous purchase orders. Inventory levels stood at A$10.3 million, reflecting ongoing production and sales activity. The company also anticipates receiving approximately A$1.3 million in R&D tax incentives in Q1 FY26, providing further financial support.
While revenue recognition lags purchase orders and cash receipts due to installation and training timelines, the recent operational improvements and financing arrangements position CurveBeam well for scaling its business in the coming year.
Bottom Line?
CurveBeam’s improving cash flow and near-term financing deal set the stage for accelerated growth, but validation timing and revenue recognition remain key watchpoints.
Questions in the middle?
- When will the enhanced HiRise™ validation process with the robotic surgical vendor be completed?
- How will the vendor financing facility impact CurveBeam’s sales and leasing strategy in North America and Europe?
- What is the expected timeline and market impact of FDA clearance for the bone mineral density module?
